Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: a pilot study

Area of Science:

• Hematology
• Oncology
• Pediatric Oncology

Background:

• Acute nonlymphocytic leukemia (ANLL) historically has a high relapse rate and mortality in pediatric and young adult patients.
• Improving treatment outcomes for ANLL in this age group remains a critical challenge in hematologic oncology.

Purpose of the Study:

• To evaluate the efficacy of cyclophosphamide and high-dose rate total body irradiation followed by allogeneic bone marrow transplantation (BMT) in children and young adults with ANLL.
• To assess long-term survival, relapse rates, and quality of life in ANLL patients treated with this regimen.

Main Methods:

• Seventeen patients (ages 6-28) with ANLL in first remission received cyclophosphamide and 750 rad total body irradiation at 26 rad/min.
• Allogeneic bone marrow transplantation from HLA-matched sibling donors was performed, followed by graft-versus-host disease (GVHD) prophylaxis.
• Patient outcomes were monitored for median follow-up of 20+ months.

Main Results:

• Seventy percent of patients achieved complete continuous remission.
• Actuarial relapse-free survival was 76% at 1 year and 64% at 5 years.
• Complications included 6% interstitial pneumonitis and 29% GVHD; survivors demonstrated excellent quality of life with high Karnofsky scores.

Conclusions:

• High-dose rate total body irradiation combined with cyclophosphamide and allogeneic BMT offers a promising approach for achieving long-term, complication-free survival in pediatric and young adult ANLL patients.
• This treatment strategy may significantly improve outcomes for a substantial proportion of young individuals diagnosed with ANLL.